Melanoma Clinical Trials in San Francisco

Showing 121-140 of 174 trials

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

NCT01425008

This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard therapies or for whom no approved therapy is available. The Dose Expansion phase will include participants with metastatic melanoma.

MelanomaMetastatic MelanomaSolid Tumor+1 more

Millennium Pharmaceuticals, Inc.149 participantsStarted Sep 2011

San Francisco, California, United States • Denver, Colorado, United States • Augusta, Georgia, United States +13 more locations

COMPLETEDPhase 2< 1 mile

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

NCT01363206

The study is an open-label, single arm single Center Phase II study to evaluate the safety and efficacy of the combination of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF, Leukine) and Ipilimumab (Yervoy) as therapy for patients with unresectable metastatic malignant melanoma.

Malignant Melanoma, Metastatic

Lynn E. Spitler, MD29 participantsStarted May 2011

San Francisco, California, United States • Rochester, Minnesota, United States

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

Melanoma Trials in Other Cities

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

A Study of Vemurafenib in Participants With Metastatic Melanoma

Other Conditions in San Francisco